Created at Source Raw Value Validated value
June 25, 2024, noon usa

1. medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. 2. allergic to any component of the research vaccines, or a history of hypersensitivity or serious reactions to vaccination. 3. women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan in this study. 4. suffering from acute febrile disease, infectious disease, or sars infection history 5. serious cardiovascular disease, such as arrhythmia, conduction block, myocardial infarction, severe hypertension, which cannot be controlled by medication (systolic blood pressure ≥180mmhg, diastolic blood pressure ≥110mmhg) 6. have severe chronic diseases or unstable condition ( grade 3 or higher as defined in the guidelines for the classification of adverse events in clinical trials for prophylactic vaccines), such as diabetes, thyroid disease and so on. 7. congenital or acquired angioedema / neuroedema. 8. had urticaria one year before this vaccination. 9. asplenia or functional asplenia. 10. thrombocytopenia or other clotting disorder (this may contraindicate intramuscular injection). 11. faintng during acupuncture treatment 12. received immunosuppressant therapy, antiallergic therapy, cytotoxic therapy, high dose inhaled corticosteroid over the past 6 months (excluding corticosteroid spray for allergic rhinitis, surface corticosteroid for acute non-complicated dermatitis, and corticosteroid with dose less than 20mg/ day) 13. received blood products within 4 months before vaccination. 14. received other investigational drugs within 1 month prior to receiving the investigational vaccines. 15. received other live attenuated vaccines within 1 month prior to receiving the investigational vaccines. 16. received subunit or inactivated vaccine within 14 days prior to receiving investigational vaccine. 17. be receiving anti-tuberculosis treatment 18. have the history of sars-cov-2 infection or covid-19 19. any medical, psychological, social or other conditions that, in the investigator's judgment, are inconsistent with the study protocol or affect the subjects' informed consent

1. medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. 2. allergic to any component of the research vaccines, or a history of hypersensitivity or serious reactions to vaccination. 3. women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan in this study. 4. suffering from acute febrile disease, infectious disease, or sars infection history 5. serious cardiovascular disease, such as arrhythmia, conduction block, myocardial infarction, severe hypertension, which cannot be controlled by medication (systolic blood pressure ≥180mmhg, diastolic blood pressure ≥110mmhg) 6. have severe chronic diseases or unstable condition ( grade 3 or higher as defined in the guidelines for the classification of adverse events in clinical trials for prophylactic vaccines), such as diabetes, thyroid disease and so on. 7. congenital or acquired angioedema / neuroedema. 8. had urticaria one year before this vaccination. 9. asplenia or functional asplenia. 10. thrombocytopenia or other clotting disorder (this may contraindicate intramuscular injection). 11. faintng during acupuncture treatment 12. received immunosuppressant therapy, antiallergic therapy, cytotoxic therapy, high dose inhaled corticosteroid over the past 6 months (excluding corticosteroid spray for allergic rhinitis, surface corticosteroid for acute non-complicated dermatitis, and corticosteroid with dose less than 20mg/ day) 13. received blood products within 4 months before vaccination. 14. received other investigational drugs within 1 month prior to receiving the investigational vaccines. 15. received other live attenuated vaccines within 1 month prior to receiving the investigational vaccines. 16. received subunit or inactivated vaccine within 14 days prior to receiving investigational vaccine. 17. be receiving anti-tuberculosis treatment 18. have the history of sars-cov-2 infection or covid-19 19. any medical, psychological, social or other conditions that, in the investigator's judgment, are inconsistent with the study protocol or affect the subjects' informed consent

April 7, 2022, 9:30 p.m. usa

medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. allergic to any component of the research vaccines, or a history of hypersensitivity or serious reactions to vaccination. women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan in this study. suffering from acute febrile disease, infectious disease, or sars infection history serious cardiovascular disease, such as arrhythmia, conduction block, myocardial infarction, severe hypertension, which cannot be controlled by medication (systolic blood pressure ≥180mmhg, diastolic blood pressure ≥110mmhg) have severe chronic diseases or unstable condition ( grade 3 or higher as defined in the guidelines for the classification of adverse events in clinical trials for prophylactic vaccines), such as diabetes, thyroid disease and so on. congenital or acquired angioedema / neuroedema. had urticaria one year before this vaccination. asplenia or functional asplenia. thrombocytopenia or other clotting disorder (this may contraindicate intramuscular injection). faintng during acupuncture treatment received immunosuppressant therapy, antiallergic therapy, cytotoxic therapy, high dose inhaled corticosteroid over the past 6 months (excluding corticosteroid spray for allergic rhinitis, surface corticosteroid for acute non-complicated dermatitis, and corticosteroid with dose less than 20mg/ day) received blood products within 4 months before vaccination. received other investigational drugs within 1 month prior to receiving the investigational vaccines. received other live attenuated vaccines within 1 month prior to receiving the investigational vaccines. received subunit or inactivated vaccine within 14 days prior to receiving investigational vaccine. be receiving anti-tuberculosis treatment have the history of sars-cov-2 infection or covid-19 any medical, psychological, social or other conditions that, in the investigator's judgment, are inconsistent with the study protocol or affect the subjects' informed consent

medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. allergic to any component of the research vaccines, or a history of hypersensitivity or serious reactions to vaccination. women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan in this study. suffering from acute febrile disease, infectious disease, or sars infection history serious cardiovascular disease, such as arrhythmia, conduction block, myocardial infarction, severe hypertension, which cannot be controlled by medication (systolic blood pressure ≥180mmhg, diastolic blood pressure ≥110mmhg) have severe chronic diseases or unstable condition ( grade 3 or higher as defined in the guidelines for the classification of adverse events in clinical trials for prophylactic vaccines), such as diabetes, thyroid disease and so on. congenital or acquired angioedema / neuroedema. had urticaria one year before this vaccination. asplenia or functional asplenia. thrombocytopenia or other clotting disorder (this may contraindicate intramuscular injection). faintng during acupuncture treatment received immunosuppressant therapy, antiallergic therapy, cytotoxic therapy, high dose inhaled corticosteroid over the past 6 months (excluding corticosteroid spray for allergic rhinitis, surface corticosteroid for acute non-complicated dermatitis, and corticosteroid with dose less than 20mg/ day) received blood products within 4 months before vaccination. received other investigational drugs within 1 month prior to receiving the investigational vaccines. received other live attenuated vaccines within 1 month prior to receiving the investigational vaccines. received subunit or inactivated vaccine within 14 days prior to receiving investigational vaccine. be receiving anti-tuberculosis treatment have the history of sars-cov-2 infection or covid-19 any medical, psychological, social or other conditions that, in the investigator's judgment, are inconsistent with the study protocol or affect the subjects' informed consent